 |  | |
|
Aroplatin in Solid Malignancies or B-Cell LymphomaProtocol #C-726-05This section has been developed to answer commonly asked questions about the Phase 1 research study evaluating Aroplatin as a treatment for solid tumors and B-cell lymphoma such as:
What is Aroplatin?Aroplatin is an investigational liposomal formulation of an advanced platinum chemotherapeutic that is currently being evaluated in clinical trials. What’s the difference between Aroplatin and other treatments?Aroplatin is a third-generation liposome-encapsulated platinum compound developed for the treatment of cancer. It is designed to reduce certain types of toxicities typically associated with other platinum agents as well as to overcome drug resistance. What will the Aroplatin study be testing?This open label, single-arm Phase 1 study is being conducted to establish dosing for a new formulation of Aroplatin, and to evaluate the safety and pharmacokinetic profile of the drug.
Am I eligible for the research study with Aroplatin?Good candidates for the study are patients with advanced solid tumors or B-cell lymphoma. The best way to find out if you’re eligible is to speak with your doctor, who can help you determine if this study is right for you. If I enroll in the study, will I definitely receive Aroplatin?Because this is a single-arm, Phase 1 study, all patients enrolled and eligible for the trial will receive Aroplatin, the investigational treatment under study. No placebo or alternative treatments will be given in this trial. What is treatment with Aroplatin like?Aroplatin is administered intravenously. According to the protocol, enrolled patients will receive Aroplatin intravenously once every four weeks until disease progression or unacceptable toxicity. Will my insurance cover the cost of participating in the study?While you are participating in the research study, any procedures that are required by the study protocol will either be covered by your insurance (as part of your usual medical care) or by Antigenics. Talk with your doctor for more details. How do I enroll in the study?If you are interested in enrolling in this study, speak with your doctor to find out if it’s right for you. For more information on the study, visit www.clinicaltrials.gov, or call the Antigenics Research Study Hotline toll-free at 866.805.8994.
| |||||||||
